At the Heart of Immune Checkpoint Inhibitor–Induced Immune Toxicity
- 1 March 2021
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 11 (3), 537-539
- https://doi.org/10.1158/2159-8290.cd-21-0091
Abstract
Summary: Wei and colleagues showcase a genetic mouse model of immune-mediated myocarditis that shares homology with immune checkpoint inhibitor (CPI)–induced myocarditis in patients with cancer. They demonstrate that abatacept (CTLA4–Ig) limits cardiac toxicity in the mouse model and, thus, may ameliorate the CPI-induced myocarditis in patients with cancer while potentially maintaining antitumor activity. See related article by Wei et al., p. 614.Keywords
This publication has 11 references indexed in Scilit:
- A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitors-Associated Myocarditis and Supports a Mechanism-Based Therapeutic InterventionCancer Discovery, 2020
- Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 AntibodyJournal of Clinical Oncology, 2019
- Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapyNature, 2019
- BLT-Immune Humanized Mice as a Model for Nivolumab-Induced Immune-Mediated Adverse Events: Comparison of the NOG and NOG-EXL StrainsToxicological Sciences, 2019
- Abstract PR07: Developing syngeneic NOD tumor models to profile immunotoxicity and antitumor immunity in response to cancer immunotherapies in autoimmune-prone miceCancer Immunology Research, 2019
- The Balancing Act between Cancer Immunity and Autoimmunity in Response to ImmunotherapyCancer Immunology Research, 2018
- Myocarditis in Patients Treated With Immune Checkpoint InhibitorsJournal of the American College of Cardiology, 2018
- PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skinScientific Reports, 2018
- Fulminant Myocarditis with Combination Immune Checkpoint BlockadeThe New England Journal of Medicine, 2016
- Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of CancerCancer Research, 2016